Nasal swine flu vaccine recalled over potency

Dec 22, 2009

(AP) -- Drugmaker Medimmune is recalling nearly 5 million doses of swine flu vaccine because the nasal spray appears to lose strength over time.

The Food and Drug Administration said Tuesday that the vaccine is safe and patients who received the product should be protected from the H1N1 virus.

The FDA says the vast majority of the doses have already been distributed and used. Agency officials say the vaccine met potency specifications when it was distributed in October and November.

Last week, another vaccine maker recalled shots for children because tests indicated those doses lost some strength.

Explore further: FDA approves second vaccine against meningitis strain

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Kids' Swine flu shots recalled; not strong enough

Dec 15, 2009

(AP) -- Hundreds of thousands of swine flu shots for children have been recalled because tests indicate the vaccine doses lost some strength, government health officials said Tuesday.

Flu season: How many shots?

Aug 30, 2009

(AP) -- Doctors don't know yet if it will take one dose or two of vaccine to protect against the new swine flu. Add that to vaccine for the regular winter flu, and it could be a multishot season for a lot of people - or ...

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.